Cancer susceptibility genes. How strong is the evidence?

Datum dogodka: 
četrtek, 24. maj 2018 - 13:00
Lokacija predavanja: 
IBMI
Predavatelj: 
Prof John O'Quigley, Sorbonne University, Pariz, Francija

We consider the case of a 25-year old carrier of the breast cancer susceptibility genes; BRCA1 and BRCA2. On the basis of observed mutations it is believed that the carrier has an 87% chance of developing breast cancer. Currently, the most commonly prescribed treatment is for a double mastectomy. The popularity of this procedure has increased greatly over the last twenty years; so much so that many leading clinics in the U.S. have a waiting list in order to be tested. New genes are being discovered all the time and, many more than just BRCA1 and BRCA2 are believed to be susceptibility genes for breast cancer. It has been suggested that whole populations be screened in order to detect those individuals at increased
risk of particular cancers. This is not feasible at present and the question remains of what action to take following a positive test. In this talk we consider some of the methodology behind this work. Does preventive surgery make sense for a carrier? Does it make any sense to get tested in the first place?

Slikovna galerija: 

Na kratko o IBMI

Inštitut za biostatistiko in medicinsko informatiko (IBMI), prej Inštitut za biomedicinsko informatiko (torej tudi IBMI), je Medicinska fakulteta ustanovila leta 1973 kot izraz potrebe po izvajanju in usklajevanju del, vezanih na analizo podatkov in posredovanje informacij. Program dela in razvoja se je skozi čas prilagajal predvsem spremembam pri financiranju in tehnološkemu napredku, vendar so temeljne smernice ostale enake: inštitut se predvsem posveča dejavnostim, ki so pomembne za raziskovalno delo v medicini. Te pa lahko razdelimo na:

Kontakt

Inštitut za biostatistiko in medicinsko informatiko
Medicinska fakulteta
Univerza v Ljubljani
Vrazov trg 2, 1000 Ljubljana, Slovenija

tel: (01) 543-77-70
fax: (01) 543-77-71
email: ibmi (at) mf.uni-lj.si